iTeos Therapeutics, Inc. (NASDAQ:ITOS) Expected to Post Earnings of $0.82 Per Share

Equities analysts predict that iTeos Therapeutics, Inc. (NASDAQ:ITOSGet Rating) will announce earnings of $0.82 per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for iTeos Therapeutics’ earnings. The lowest EPS estimate is $0.57 and the highest is $1.07. iTeos Therapeutics reported earnings per share of ($0.39) in the same quarter last year, which suggests a positive year-over-year growth rate of 310.3%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that iTeos Therapeutics will report full-year earnings of $3.39 per share for the current fiscal year, with EPS estimates ranging from $1.92 to $5.14. For the next year, analysts expect that the company will report earnings of ($0.84) per share, with EPS estimates ranging from ($6.59) to $2.36. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover iTeos Therapeutics.

Separately, Zacks Investment Research cut iTeos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 26th.

NASDAQ:ITOS traded down $1.04 during trading hours on Friday, reaching $26.69. 405,665 shares of the company were exchanged, compared to its average volume of 379,940. The stock’s 50-day moving average is $33.44 and its 200-day moving average is $35.06. The firm has a market cap of $947.76 million, a PE ratio of 4.77 and a beta of 1.91. iTeos Therapeutics has a twelve month low of $17.43 and a twelve month high of $52.43.

In other news, insider Joanne Jenkins Lager sold 3,500 shares of the company’s stock in a transaction on Friday, February 11th. The stock was sold at an average price of $35.85, for a total value of $125,475.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Michel Detheux sold 11,500 shares of the stock in a transaction dated Monday, April 18th. The stock was sold at an average price of $31.87, for a total value of $366,505.00. Following the transaction, the chief executive officer now owns 26,263 shares in the company, valued at $837,001.81. The disclosure for this sale can be found here. Insiders sold a total of 636,638 shares of company stock worth $22,389,373 over the last quarter. Company insiders own 3.95% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ITOS. Lindbrook Capital LLC purchased a new position in iTeos Therapeutics during the fourth quarter worth about $43,000. Royal Bank of Canada lifted its position in iTeos Therapeutics by 42.8% during the second quarter. Royal Bank of Canada now owns 2,474 shares of the company’s stock worth $63,000 after buying an additional 742 shares during the period. Nisa Investment Advisors LLC purchased a new position in iTeos Therapeutics during the fourth quarter worth about $95,000. Robeco Institutional Asset Management B.V. purchased a new position in iTeos Therapeutics during the first quarter worth about $97,000. Finally, Lazard Asset Management LLC purchased a new position in iTeos Therapeutics during the fourth quarter worth about $178,000.

About iTeos Therapeutics (Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Read More

Get a free copy of the Zacks research report on iTeos Therapeutics (ITOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.